rabeprazole has been researched along with Zollinger-Ellison Syndrome in 6 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Zollinger-Ellison Syndrome: A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the dose of rabeprazole that decreased basal acid output to safe levels in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion." | 9.12 | An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. ( Bjaaland, T; Humphries, T; Merrouche, M; Mignon, M; Morocutti, A, 2006) |
| " Rabeprazole is a potent and irreversible inhibitor of H(+)/K(+)-ATPase gastric pump, and it is indicated for the treatment of gastroesophageal reflux disease, Zollinger Ellison syndrome, duodenal and gastric ulcers and for the eradication of Helicobacter pylori in combination with antibiotics." | 4.88 | Rabeprazole for the treatment of acid-related disorders. ( Marelli, S; Pace, F, 2012) |
| " In 8-week studies, among patients with gastro-oesophageal reflux disease (GORD), rabeprazole 20 mg/day or 10mg twice daily was as effective as omeprazole and superior to ranitidine in the healing of GORD." | 4.81 | Rabeprazole: an update of its use in acid-related disorders. ( Carswell, CI; Goa, KL, 2001) |
| "We examined 27 patients with hypochlorhydria or achlorhydria based on a predefined basal acid output (BAO) measurement of less than 5." | 1.39 | Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. ( Metz, DC; Shah, P; Singh, MH; Yang, YX, 2013) |
| "Rabeprazole is a proton pump inhibitor (PPI) presenting a very advantageous pharmacodynamic and pharmacokinetic profile over older PPIs." | 1.35 | Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. ( Marelli, S; Pace, F; Pallotta, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shah, P | 1 |
| Singh, MH | 1 |
| Yang, YX | 1 |
| Metz, DC | 1 |
| Ebbelaar, CF | 1 |
| Lammers, HA | 1 |
| Schobben, AF | 1 |
| Pallotta, S | 1 |
| Pace, F | 2 |
| Marelli, S | 2 |
| Morocutti, A | 1 |
| Merrouche, M | 1 |
| Bjaaland, T | 1 |
| Humphries, T | 1 |
| Mignon, M | 1 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
2 reviews available for rabeprazole and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
Rabeprazole for the treatment of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Enzyme Inhibitors; Gastroesophageal Refl | 2012 |
Rabeprazole: an update of its use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2001 |
1 trial available for rabeprazole and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Enzyme Inhibitors; Female; Gastric A | 2006 |
3 other studies available for rabeprazole and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Fe | 2013 |
[Switching to a generic drugA blessing or a curse?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drugs, Generic; Esomeprazole; Humans; Pa | 2016 |
Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Gastroesophageal Reflux; Humans; Proton | 2008 |